Wang Weidong, Li Chunling, Kwon Tae-Hwan, Knepper Mark A, Frøkiaer Jørgen, Nielsen Søren
The Water and Salt Research Center, University of Aarhus, DK-8000 Aarhus C, Denmark.
Am J Physiol Renal Physiol. 2002 Dec;283(6):F1313-25. doi: 10.1152/ajprenal.00040.2002. Epub 2002 Jul 30.
The purpose of this study was to evaluate whether hypercalcemia is associated with downregulation of renal aquaporins (AQPs), including AQP1, AQP2, phosphorylated AQP2 (p-AQP2), AQP3, and AQP4, and if this is the case, to test whether cAMP-phosphodiesterase (PDE) inhibitor treatment can prevent AQP downregulation and prevent the development of polyuria. Vitamin D-induced hypercalcemia in rats was associated with increased urine output and reduced urine osmolality, consistent with previous findings (Levi M, Peterson L, and Berl T. Kidney Int 23: 489-497, 1983). Semiquantitative immunoblotting revealed a significant reduction in the abundance of inner medullary AQP2 (52 +/- 6% of control levels), consistent with previous studies, and of AQP2, which is phosphorylated at the PKA phosphorylation consensus site serine 256 (p-AQP2; 36 +/- 8%). Moreover, AQP3 abundance was also significantly decreased (45 +/- 7 and 61 +/- 6% of control levels in inner medulla and whole kidney, respectively). Consistent with this, immunohistochemistry demonstrated reduced AQP3 immunolabeling along the entire collecting duct. AQP4 expression was not reduced. Surprisingly, total kidney AQP1 abundance was also reduced (60 +/- 6%). AQP1 expression was reduced in the cortex and outer stripe of the outer medulla (48 +/- 7%; i.e., in proximal tubules). In contrast, AQP1 levels were not changed in the inner stripe of the outer medulla or in the inner medulla (i.e., descending thin limbs and vasa recta). Treatment with the cAMP-PDE inhibitors rolipram and milrinone in combination (inhibiting PDE IV and PDE III isoenzymes) at day 2 and onward completely prevented the hypercalcemia-induced downregulation of AQP2 and AQP3 (but not AQP1) and completely prevented the development of polyuria. In conclusion, AQP3, AQP2, and p-AQP2 are downregulated and are likely to play critical roles in the development of polyuria associated with vitamin D-induced hypercalcemia. Moreover, PDE inhibitor treatment significantly prevented the reduced expression of collecting duct AQPs and prevented the development of polyuria.
本研究的目的是评估高钙血症是否与肾水通道蛋白(AQP)下调有关,这些水通道蛋白包括AQP1、AQP2、磷酸化AQP2(p-AQP2)、AQP3和AQP4;如果是这样的话,测试环磷酸腺苷磷酸二酯酶(PDE)抑制剂治疗是否可以预防AQP下调并防止多尿的发生。维生素D诱导的大鼠高钙血症与尿量增加和尿渗透压降低有关,这与先前的研究结果一致(Levi M、Peterson L和Berl T。《肾脏国际》23: 489 - 497,1983)。半定量免疫印迹显示,髓质内AQP2丰度显著降低(为对照水平的52±6%),这与先前的研究一致,PKA磷酸化共有位点丝氨酸256处磷酸化的AQP2(p-AQP2;36±8%)也是如此。此外,AQP3丰度也显著降低(髓质内和全肾分别为对照水平的45±7%和61±6%)。与此一致的是,免疫组织化学显示整个集合管的AQP3免疫标记减少。AQP4表达未降低。令人惊讶的是,全肾AQP1丰度也降低了(60±6%)。AQP1表达在皮质和外髓质外层减少(48±7%;即在近端小管中)。相比之下,外髓质内层或髓质内(即降支细段和直小血管)的AQP1水平未改变。在第2天及之后联合使用环磷酸腺苷PDE抑制剂咯利普兰和米力农(抑制PDE IV和PDE III同工酶)完全预防了高钙血症诱导的AQP2和AQP3下调(但不包括AQP1),并完全预防了多尿的发生。总之,AQP3、AQP2和p-AQP2下调,可能在维生素D诱导的高钙血症相关的多尿发生中起关键作用。此外,PDE抑制剂治疗显著预防了集合管AQP表达的降低并预防了多尿的发生。